International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 193-199
THE RELATIONSHIP BETWEEN MEAN PLATELET VOLUME, IN-VITRO PLATELET FUNCTION TESTS AND MICROVASCULAR COMPLICATIONS IN TYPE II DIABETES MELLITUS
SELAHATTİN AYDINLI1, GÜRAY SAYDAM1, FAHRİ ŞAHİN1, MEHMET TÜZÜN1, FİLİZ BÜYÜKKEÇECİ1
Ege Üniversitesi Tıp Fakültesi, İç Hastalıkları AD, İZMİR
Keywords: type ıı diabetes mellitus, microvascular complications, platelet volume and aggregation
Vascular complications in the course of type II diabetes mellitus are the most important causes of mortality and morbidity. Many different factors such as hemodynamic, neurohumoral, metabolic factors and cytokines have attributed to diabetic vasculopathy. Recently, the role of platelets in diabetic vasculopathy has been shown. In this study, we aimed to investigate the platelet function tests in diabetic patients according to their complications and, mean platelet volume and in-vitro platelet aggregations in patients with type II diabetes mellitus. Fifty two diabetic patients with complications and 48 patients without complications were included into this study. Mean platelets volume measurements and in-vitro platelet aggregations with ADP, collagen and epinephrine were obtained in all patients. As a result; there are no statistically differences between the group with complications and the group without any complications in the aspect of mean platelet volumes and in-vitro aggregation tests. Although the role of platelets regarding diabetic complications in diabetic patients is well-known phenomenon , we could not find any differences between the complication and non-complication group. This could be explained by the differences between in-vitro aggregation and in-vivo platelet functions. In-vitro platelet aggregation tests can not exactly reflect the in-vivo platelet functions in different disease and patients. The another mechanism for explanation this phenomenon could be the rapid consumption of activated platelets from blood circulation in diabetic patients with complications. Further studies are needed to explain the in-vivo role of platelets in diabetic complications.
SELAHATTİN AYDINLI1, GÜRAY SAYDAM1, FAHRİ ŞAHİN1, MEHMET TÜZÜN1, FİLİZ BÜYÜKKEÇECİ1
Ege Üniversitesi Tıp Fakültesi, İç Hastalıkları AD, İZMİR
Keywords: type ıı diabetes mellitus, microvascular complications, platelet volume and aggregation
Vascular complications in the course of type II diabetes mellitus are the most important causes of mortality and morbidity. Many different factors such as hemodynamic, neurohumoral, metabolic factors and cytokines have attributed to diabetic vasculopathy. Recently, the role of platelets in diabetic vasculopathy has been shown. In this study, we aimed to investigate the platelet function tests in diabetic patients according to their complications and, mean platelet volume and in-vitro platelet aggregations in patients with type II diabetes mellitus. Fifty two diabetic patients with complications and 48 patients without complications were included into this study. Mean platelets volume measurements and in-vitro platelet aggregations with ADP, collagen and epinephrine were obtained in all patients. As a result; there are no statistically differences between the group with complications and the group without any complications in the aspect of mean platelet volumes and in-vitro aggregation tests. Although the role of platelets regarding diabetic complications in diabetic patients is well-known phenomenon , we could not find any differences between the complication and non-complication group. This could be explained by the differences between in-vitro aggregation and in-vivo platelet functions. In-vitro platelet aggregation tests can not exactly reflect the in-vivo platelet functions in different disease and patients. The another mechanism for explanation this phenomenon could be the rapid consumption of activated platelets from blood circulation in diabetic patients with complications. Further studies are needed to explain the in-vivo role of platelets in diabetic complications.